|Year : 2020 | Volume
| Issue : 10 | Page : 464-466
Performance and correlation of interferon gamma release assays and tuberculin skin test in HIV-infected children and adolescents with immune reconstitution
Keswadee Lapphra1, Rati Diwitaya1, Sansnee Senawong2, Maneeprang Thovarabha2, Parnwas Pinnobphun3, Alan Maleesatharn1, Nantaka Kongstan1, Benjawan Khumcha1, Wanatpreeya Phongsamart1, Orasri Wittawatmongkol1, Supattra Rungmaitree1, Kulkanya Chokephaibulkit1
1 Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
2 Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
3 Biomed Diagnostics (Thailand) Co LTD, Bangkok, Thailand
|Date of Submission||20-Aug-2018|
|Date of Decision||17-Nov-2019|
|Date of Acceptance||12-Dec-2019|
|Date of Web Publication||14-Aug-2020|
Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Source of Support: This study was supported by the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, [Grant Number (IO) R015832028)]. Oxford Immunotec and Biomed diagnostics (Thailand) provided the T-SPOT.TB test kit, Conflict of Interest: None
Objective: To evaluate the performance of interferon gamma release assays and tuberculin skin test in HIV-infected children and adolescents with immune reconstitution.
Methods: A cross-sectional study was conducted in HIV-infected patients aged 5-18 years receiving antiretroviral treatment with CD4 T-lymphocytes >25% or >500 cells/mm3 for at least 6 months. QuantiFERON-TB Gold, T-SPOT.TB, and tuberculin skin test were performed in each patient.
Results: A total of 50 patients were enrolled with median age of 13.7 years, CD4 counts of 753 (IQR: 587-989) cells/mm3. Among 27 patients with tuberculosis (16) or tuberculosis exposure (11), 8 (29.6%) were positive to at least one test, 2 (7.4%) were positive QuantiFERON-TB Gold, 3 (11.1%) positive T-SPOT.TB, and 7 (25.9%) had tuberculin skin test ≥5 mm. Among 23 patients without history of tuberculosis or exposure, all had negative interferon gamma release assays, while 2 (8.7%) had positive tuberculin skin test.
Conclusions: All tests had low sensitivity despite immune reconstitution.
Keywords: Children; HIV; TB; Interferon gamma release assays; Tuberculin skin test
|How to cite this article:|
Lapphra K, Diwitaya R, Senawong S, Thovarabha M, Pinnobphun P, Maleesatharn A, Kongstan N, Khumcha B, Phongsamart W, Wittawatmongkol O, Rungmaitree S, Chokephaibulkit K. Performance and correlation of interferon gamma release assays and tuberculin skin test in HIV-infected children and adolescents with immune reconstitution. Asian Pac J Trop Med 2020;13:464-6
|How to cite this URL:|
Lapphra K, Diwitaya R, Senawong S, Thovarabha M, Pinnobphun P, Maleesatharn A, Kongstan N, Khumcha B, Phongsamart W, Wittawatmongkol O, Rungmaitree S, Chokephaibulkit K. Performance and correlation of interferon gamma release assays and tuberculin skin test in HIV-infected children and adolescents with immune reconstitution. Asian Pac J Trop Med [serial online] 2020 [cited 2022 Aug 11];13:464-6. Available from: https://www.apjtm.org/text.asp?2020/13/10/464/291040
| 1. Introduction|| |
The majority of children and adolescents living with HIV are at risk of tuberculosis (TB). Treatment of latent TB infection (LTBI) in this high-risk populations is a critical strategy towards the mission to end TB. Immunosuppression can alter the reaction of interferon-gamma release assays (IGRA) and tuberculin skin test (TST) utilized for LTBI diagnosis and this may lead to a missed opportunity to provide treatment to prevent TB. It is hypothesized that following immune reconstitution with antiretroviral therapy (ART) that individuals living with HIV will react well to IGRA and TST tests.
| 2. Materials and methods|| |
This was a cross-sectional study at a pediatric HIV clinic, Siriraj Hospital, in Bangkok, Thailand. The study was approved by the Institute Review Board (Certificate of approval number Si077/2015). We enrolled children with HIV aged 5-18 years on ART for at least 1 year, with evidence of immune reconstitution, defined as a CD4 >25% or >500 cells/mm3 for at least 6 months. Those having any other condition that may affect immunologic function in the preceding 6 weeks were excluded. Study procedures included two visits: the first visit included a physical examination, checking for BCG scar and vaccination records, chest X-ray, collection of a single blood sample for the two IGRA tests, QFT-GIT (Cellestis Limited, Australia) and T-SPOT.TB (Oxford Immunotec, Oxford, UK), and TST placement using 0.1 mL of PPD RT23 (Staten Serum Institute, Denmark) via intradermal injection. At the second visit, 48-72 h later, the TST reaction was read (the same person read the TST reactions throughout the study). Reactions of ≥5 mm induration were considered positive. Subjects were classified into three categories based on their medical history: (1) TB (including definite, probable, or possible TB), (2) TB exposure with household members without symptom and normal chest X-ray, and (3) no TB or TB exposure.
Data were analyzed using STATA Version 11.2 (Stata Corp LP, TX, USA). Agreement between the QFT-GIT and T-SPOT.TB, and between TST and IGRA were determined by Cohen’s kappa coefficient (κ). Concordance between all tests was defined as the percentage of concordant results (positive or negative) in the same subjects.
| 3. Results|| |
A total of 50 children and adolescents with HIV were enrolled (64.0% male) with a median age of 13.7 years [Figure 1]. All subjects reported receiving BCG vaccination at birth. Forty (80.0%) of subjects had moderate to severe nadir CD4 suppression. The median CD4 count at enrollment was 753 (IQR: 587-989) cells/mm3. The median duration of CD4 count ≥500 cells/mm3 or >25% was 93.3 (IQR: 67.2-139.1) months. All subjects were receiving ART [median duration 104.6 (IQR: 83.3-142.8) months] and the median age of ART initiation was 3.4 (IQR: 1.1-7.4) years. All subjects were virologically suppressed [median duration 78 (IQR: 46.9-93.8) months]. Sixteen (32.0%) subjects had a history of TB, 10 probable and 6 definite; all were diagnosed more than one year prior to enrollment. Eleven (22.0%) subjects were household TB-exposed; 9 were exposed more than one year prior to enrollment.
All children with TB and TB exposure complete the appropriate TB treatment.
Among the 27 subjects who had TB or TB exposure, 8 (29.6%) children had a positive results to at least one of the IGRA tests or TST. Of these, 2 (7.4%) had positive QFT-GIT, 3 (11.1%) had positive T-SPOT.TB, and 7 (25.9%) had positive TST results. Among those with no history of TB or TB exposure, none had a positive IGRA test, while 2 (8.7%) had a positive TST.
More subjects with TB/TB exposure had positive test results of either IGRA or TST compared to those without TB/TB exposure (29.6% vs. 8.7%, P=0.08). Overall agreement between QFT-GIT, T-SPOT.TB, and TST were slight to fair: κ=0.12 for QFT-GIT vs. TST (P=0.11), κ=0.23 for T-SPOT.TB vs. TST (P=0.02). The agreement between QFT-GIT vs. T-SPOT.TB was good (κ=0.65, P<0.01 for all patients, and κ=0.78, P<0.01 in TB/TB-exposed patients). No independent factor associated with negative test results for both IGRA and TST was identified.
In subjects without TB/TB exposure, although the concordance between tests were high (87.0%), the agreement between any of the tests was difficult to interpret due to the few positive results [Table 1].
|Table 1: Agreement and overall concordance of QFT-GIT, T-SPOT.TB and TST ≥5 mm.|
Click here to view
| 4. Discussion|| |
We found in children and adolescents living with HIV on ART with immune reconstitution that IGRA and TST had low sensitivity and the concordance between two IGRA and TST was 80.0%, most of which was driven by negative results. Agreement between each IGRA test and TST were slight to fair, and agreement between the two IGRA tests was good.
Early diagnosis and treatment of LTBI is an essential component of the WHO strategy to control TB,, but the diagnostic test is still challenging. We found only a third of children with a history of TB or TB exposure were positive to at least of the two IGRA tests or TST; and IGRA tests were less likely to be positive than TST. There are a few published studies exploring the performance of IGRA in children with HIV and our results add to this limited knowledge. While QFT-GIT and T-SPOT.TB results had 96% concordance, the two IGRA tests had only 80% concordance with TST at 5 mm.
A study of QFT-GIT in children with HIV in Botswana reported similar results to our study with IGRA positive rates around 10%, and TST positive rates around 25%, in children with prior TB/LTBI, despite suppressed viral load and normalized CD4 counts in an area with a high prevalence of TB. Altogether it is suggested that T-cell dysfunction remain despite ‘normalized’ CD4 counts. Reversion (the change to a negative TST following a previous positive result) is uncommon in healthy individuals, occurring in less than 10%. The reversion rate is unknown in people with HIV.
In conclusion, both IGRA tests and TST had low sensitivity; positive rate at best using combination of the tests was only one third of those who had prior TB/TB exposure. IGRA and TST may not be reliable to detect LTBI or TB in children and adolescents with HIV even after immune reconstitution.
Conflict of interest statement
The authors declare they have no personal or professional conflicts of interest regarding any aspect of this study.
The authors thank Tim R. Cressey, PhD (PHPT/IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand) for his contribution to the manuscript.
This study was supported by the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, [Grant Number (IO) R015832028)]. Oxford Immunotec and Biomed diagnostics (Thailand) provided the T-SPOT.TB test kit.
KL, KC, and RD designed, performed study procedures and analyzed data. KL, RD, NK, and BK established the cohort including subject finding, invitation, and inform consent process. SS, MT, and PP performed IGRA tests. AM assisted with data analysis. All authors provided clinical care and contributed to manuscript writing.
| References|| |
ATS/CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep
Tieu HV, Suntarattiwong P, Puthanakit T, Chotpitayasunondh T, Chokephaibulkit K, Sirivichayakul S, et al. Comparing interferon-gamma release assays to tuberculin skin test in Thai children with tuberculosis exposure. PLoS One
Viera AJ, Garrett JM. Understanding interobserver agreement: The kappa statistic. Fam Med
Caldwell MB, Oxtoby MJ, Simonds RJ, Lindegren ML, Rogers M, Division of HIV/AIDS National Center for Infectious Diseases, et al. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep
Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep
Cruz AT, Marape M, Gravis EA, Starke JR. Performance of the QuantiFERON-TB gold interferon gamma release assay among HIV-infected children in Botswana. J Int Assoc Provid AIDS Care
Knox KS, Day RB, Kohli LM, Hage CA, Twigg HL 3rd. Functional impairment of CD4 T cells despite normalization of T cell number in HIV. Cell Immunol
Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med